hVIVO PLC (LSE:HVO) - Share price - Overview

Stock Report

hVIVO PLC HVO

Last Price
GBX116.50

Day Change
-1.00|-0.85%

As of 22/05/2017
14:35:52 BST | GBX
Minimum 15 Minutes Delay.

Last Close117.50p
Day Range115.25 - 115.25
Mkt Cap91.02Mil
52-Wk Range115.25 - 239.75
Yield %0.00
ISINGB00B6ZM0X53
Volume295
P/E-5.40
P/S4.58
P/CF-5.19

Share Price

Total Returns 26/05/2017

 Chg (%)  
More ...
hVIVO PLC-8.98 
FTSE 100 TR GBP4.15
 
Financials
201420152016
More ...
Income Statement
Turnover18.477.7219.85
Operating Profit-23.05-22.00-22.92
Net Profit-18.44-17.91-17.88
Reported EPS-31.30-26.00-22.90
Balance Sheet
Current Assets61.2763.0635.93
Non Current Assets8.2121.6920.80
Total Assets69.4884.7456.73
Current Liabilities4.6217.507.14
Total Liabilities8.3021.1210.67
Total Equity61.1863.6246.05
Cash Flow
Operating Cash Flow-19.15-13.60-22.39
Net Change in Cash9.52-8.6311.47
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2017-17.30-16.80--6.94---
2018-17.10-17.50--6.66---
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
07/04/2017PurchaseMr Jaime Ellertson128.0012,50816,010.00
07/04/2017PurchaseMr. Jim Winschel128.003,1254,000.00
09/01/2017PurchaseMr Jaime Ellertson161.0010,11416,284.00
09/01/2017PurchaseMr. Jim Winschel161.002,4843,999.00

Company Profile

hVIVO PLC and its subsidiaries is a specialty biopharma company with discovery and clinical testing capabilities, pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases.

Sector

Biotechnology

Market Position

942 of 1851 Companies

Index

Outlook

(02/05/2017) no outlook statement

Next Event 22/09/2017

Next interim announcement
Ratios
CompSecMkt
More ...
PER (E)-6.8215.0716.87
Div Yld (E)0.003.604.05
PEG (E)0.000.420.72
ROCE-48.94187.8415.97
Op Mrgn-73.12-6.501.61
EPS Grwth0.0056.9427.17
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanMr Jaime Ellertson
Chief Executive OfficerKym Denny
Chief Financial & Business Officer & CSGraham Yeatman
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.